Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.32 |
| ▸ | STAT5B | P51692 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15887428 | 1.00 | NR1D1 (0.34) | NR1D1F2CYP24A1STAT5BPPARG | |
| SCHEMBL14777287 | 0.92 | NR1D1 (0.34) | NR1D1F2CYP24A1STAT5BPPARG | |
| SCHEMBL14788887 | 0.92 | MMP13 (0.31) | MMP13 | |
| SCHEMBL8724738 | 0.79 | STAT3 (0.36) | NR1D1CYP24A1ALDH1A1TSHRKMT2A | |
| SCHEMBL14788868 | 0.73 | HDAC6 (0.32) | — | |
| SCHEMBL14788883 | 0.73 | HDAC6 (0.32) | — | |
| SCHEMBL11139640 | 0.72 | ALDH1A1 (0.37) | NR1D1F2CYP24A1STAT5BPPARG | |
| SCHEMBL11171683 | 0.71 | NR1D1 (0.38) | NR1D1CYP24A1ALDH1A1TSHRKMT2A | |
| SCHEMBL14788869 | 0.71 | CA14 (0.33) | — | |
| SCHEMBL17664852 | 0.69 | CA2 (0.47) | ALDH1A1TSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8784774-B2 | Labeled molecular imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130071332-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071332-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | SLC7A11, GLS, SLC3A2 | NR1D1 3915/4885F2 4810/4885CYP24A1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.